Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
TCR2 Therapeutics management to meet virtually with Truist » 04:55
04/12/21
04/12
04:55
04/12/21
04:55
TCRR

TCR2 Therapeutics

$22.09 /

-0.57 (-2.52%)

Virtual Meeting to be…

Virtual Meeting to be held on April 12 hosted by Truist.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$22.09 /

-0.57 (-2.52%)

TCRR TCR2 Therapeutics
$22.09 /

-0.57 (-2.52%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$22.09 /

-0.57 (-2.52%)

  • 20
    Jan
  • 29
    Jul
Hot Stocks
TCR2 Therapeutics highlights gavo-cel translational data at AACR Annual Meeting » 16:59
04/11/21
04/11
16:59
04/11/21
16:59
TCRR

TCR2 Therapeutics

$22.09 /

-0.57 (-2.52%)

TCR2 Therapeutics…

TCR2 Therapeutics announced that clinical and translational data from the dose escalation portion of the company's Phase 1/2 clinical trial of gavo-cel in patients with treatment refractory mesothelin-expressing solid tumors was presented at the American Association for Cancer Research Virtual Annual Meeting. In addition, the company said that preclinical data from its autologous CD70 and allogeneic mesothelin TRuC-T cells would be highlighted in e-posters in the Adoptive Cell Therapy session at AACR. The data reported in gavo-cel poster presentation were from 8 treatment refractory mesothelin-expressing solid tumor patients, 7 mesothelioma and 1 ovarian, that received a single gavo-cel intravenous infusion at 5x107 cells/m2 or 1x108 cells/m2 either alone or following lymphodepletion with fludarabine and cyclophosphamide.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$22.09 /

-0.57 (-2.52%)

TCRR TCR2 Therapeutics
$22.09 /

-0.57 (-2.52%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$22.09 /

-0.57 (-2.52%)

  • 20
    Jan
  • 29
    Jul
Conference/Events
TCR2 Therapeutics management to meet virtually with Truist » 11:32
04/05/21
04/05
11:32
04/05/21
11:32
TCRR

TCR2 Therapeutics

$23.30 /

+0.435 (+1.90%)

Virtual Meeting to be…

Virtual Meeting to be held on April 12 hosted by Truist.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$23.30 /

+0.435 (+1.90%)

TCRR TCR2 Therapeutics
$23.30 /

+0.435 (+1.90%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$23.30 /

+0.435 (+1.90%)

  • 20
    Jan
  • 29
    Jul
Hot Stocks
TCR2 Therapeutics appoints vice president of technical operations » 08:12
03/29/21
03/29
08:12
03/29/21
08:12
TCRR

TCR2 Therapeutics

$23.29 /

+2.39 (+11.44%)

, AUTL

Autolus Therapeutics

$5.99 /

-0.13 (-2.12%)

Aaron Vernon joins TCR2…

Aaron Vernon joins TCR2 (TCRR) as Vice President of Technical Operations. Most recently, he held senior positions including Vice President of Global Technical Operations and Vice President of Engineering & Supply Chain at Autolus Therapeutics (AUTL). "The hiring of Aaron Vernon to head technical operations for the company comes at the right time as we expand our manufacturing capabilities in anticipation of commercial production. His prior leadership roles in building out commercial operations as well as his specific expertise in global supply chain management will offer vital insights to TCR2 as we continue to execute upon our clinical strategy for gavo-cel," said Garry Menzel, Ph.D., President and CEO of TCR2 Therapeutics.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$23.29 /

+2.39 (+11.44%)

AUTL Autolus Therapeutics
$5.99 /

-0.13 (-2.12%)

TCRR TCR2 Therapeutics
$23.29 /

+2.39 (+11.44%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
AUTL Autolus Therapeutics
$5.99 /

-0.13 (-2.12%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
TCRR TCR2 Therapeutics
$23.29 /

+2.39 (+11.44%)

AUTL Autolus Therapeutics
$5.99 /

-0.13 (-2.12%)

  • 10
    Feb
  • 20
    Jan
  • 29
    Jul
Hot Stocks
TCR2 Therapeutics establishes commercial-scale cell therapy facility » 08:08
03/29/21
03/29
08:08
03/29/21
08:08
TCRR

TCR2 Therapeutics

$23.29 /

+2.39 (+11.44%)

, ARE

Alexandria Real Estate

$168.94 /

-0.25 (-0.15%)

TCR2 Therapeutics (TCRR)…

TCR2 Therapeutics (TCRR) announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities (ARE) for an existing 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland which is ready for Current Good Manufacturing Practice build-out. The site will support clinical and commercial production of gavo-cel with a capacity to treat several thousand cancer patients annually. The facility is expected to accelerate the Company's commercial-scale manufacturing timelines with production anticipated in 2023. The 85,000 square foot facility constructed by Alexandria Real Estate Equities will provide space for commercial and clinical manufacturing, quality control laboratories and offices upon completion. TCR2 is designing the state-of-the-art cell therapy facility to utilize semi-automated and functionally closed systems which aim to provide cGMP manufacturing while optimizing the reliability of our cell therapy products and reducing manufacturing costs and vein-to-vein time. The flexible layout will allow production of gavo-cel and other emerging cell therapies in the TRuC-T cell pipeline.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$23.29 /

+2.39 (+11.44%)

ARE Alexandria Real Estate
$168.94 /

-0.25 (-0.15%)

TCRR TCR2 Therapeutics
$23.29 /

+2.39 (+11.44%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
ARE Alexandria Real Estate
$168.94 /

-0.25 (-0.15%)

01/07/21 Baird
Alexandria Real Estate upgraded to Outperform from Neutral at Baird
10/16/20 UBS
Alexandria Real Estate initiated with a Neutral at UBS
10/02/20 Berenberg
Alexandria Real Estate initiated with a Buy at Berenberg
09/02/20 RBC Capital
Alexandria Real Estate price target raised to $184 from $175 at RBC Capital
TCRR TCR2 Therapeutics
$23.29 /

+2.39 (+11.44%)

ARE Alexandria Real Estate
$168.94 /

-0.25 (-0.15%)

  • 20
    Jan
  • 06
    Jan
  • 29
    Jul
  • 07
    Jul
ARE Alexandria Real Estate
$168.94 /

-0.25 (-0.15%)

Hot Stocks
TCR2 Therapeutics trading resumes  15:16
03/26/21
03/26
15:16
03/26/21
15:16
TCRR

TCR2 Therapeutics

$20.13 /

-0.77 (-3.68%)

 
ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$20.13 /

-0.77 (-3.68%)

TCRR TCR2 Therapeutics
$20.13 /

-0.77 (-3.68%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$20.13 /

-0.77 (-3.68%)

  • 20
    Jan
  • 29
    Jul
Hot Stocks
TCR2 Therapeutics trading halted, volatility trading pause  15:11
03/26/21
03/26
15:11
03/26/21
15:11
TCRR

TCR2 Therapeutics

$20.07 /

-0.83 (-3.97%)

 
ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$20.07 /

-0.83 (-3.97%)

TCRR TCR2 Therapeutics
$20.07 /

-0.83 (-3.97%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$20.07 /

-0.83 (-3.97%)

  • 20
    Jan
  • 29
    Jul
Over a month ago
Syndicate
TCR2 Therapeutics files automatic mixed securities shelf  16:54
03/16/21
03/16
16:54
03/16/21
16:54
TCRR

TCR2 Therapeutics

$26.25 /

+0.18 (+0.69%)

 
ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$26.25 /

+0.18 (+0.69%)

TCRR TCR2 Therapeutics
$26.25 /

+0.18 (+0.69%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$26.25 /

+0.18 (+0.69%)

  • 20
    Jan
  • 29
    Jul
Recommendations
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho » 06:51
03/12/21
03/12
06:51
03/12/21
06:51
TCRR

TCR2 Therapeutics

$27.99 /

+0.27 (+0.97%)

Mizuho analyst Mara…

Mizuho analyst Mara Goldstein lowered the firm's price target on TCR2 Therapeutics to $51 from $58 and keeps a Buy rating on the shares post the Q4 results.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$27.99 /

+0.27 (+0.97%)

TCRR TCR2 Therapeutics
$27.99 /

+0.27 (+0.97%)

03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
12/15/20 Mizuho
TCR2 Therapeutics price target raised to $58 from $33 at Mizuho
TCRR TCR2 Therapeutics
$27.99 /

+0.27 (+0.97%)

  • 20
    Jan
  • 29
    Jul
Conference/Events
TCR2 Therapeutics management to meet virtually with Piper Sandler » 04:55
03/12/21
03/12
04:55
03/12/21
04:55
TCRR

TCR2 Therapeutics

$27.99 /

+0.27 (+0.97%)

Virtual Meeting to be…

Virtual Meeting to be held on March 12 hosted by Piper Sandler.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$27.99 /

+0.27 (+0.97%)

TCRR TCR2 Therapeutics
$27.99 /

+0.27 (+0.97%)

03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
12/15/20 Mizuho
TCR2 Therapeutics price target raised to $58 from $33 at Mizuho
TCRR TCR2 Therapeutics
$27.99 /

+0.27 (+0.97%)

  • 20
    Jan
  • 29
    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.